Kelsey Natsuhara

Statistics

Publications

Citations

321

H-Index

Active since

2017

Affiliations

University of California, San Francisco(Current)

Dana-Farber Brigham Cancer Center

Brigham and Women's Hospital

Dana-Farber Cancer Institute

UCSF Helen Diller Family Comprehensive Cancer Center

Kelsey Natsuhara is an author at University of California, San Francisco specializing in medicine, oncology, and chimeric antigen receptor t-cell therapy.

ORCID

Publications per year

2017–2023

Publications

Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy

Ying Sheng, Chiung‐Yu Huang, Sophia Bylsma et al. · Blood Advances · 2021 · 124 citations · Full text

Medicine, Hematology, Infectious Diseases +16

Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer

Stephanie M. Wong, Nora Almana, Jungeun Choi et al. · Annals of Surgical Oncology · 2019 · 93 citations

Medicine, Oncology, Breast Oncology +16

Distinct Roles for Matrix Metalloproteinases 2 and 9 in Embryonic Hematopoietic Stem Cell Emergence, Migration, and Niche Colonization

Lindsay N. Theodore, Elliott J. Hagedorn, Mauricio Cortes et al. · Stem Cell Reports · 2017 · 62 citations · Full text

Life Sciences, Cell Biology, Developmental Biology +17

Implementation of Surgeon-Initiated Gene Expression Profile Testing (Onco<i>type</i> DX) Among Patients With Early-Stage Breast Cancer to Reduce Delays in Chemotherapy Initiation

Katya Losk, Rachel A. Freedman, Nancy U. Lin et al. · Journal of Oncology Practice · 2017 · 18 citations · Full text

Medicine, Oncology, Surgery +16

Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy

Swetha Kambhampati, Bita Fakhri, Ying Sheng et al. · Blood · 2020 · 12 citations

Life Sciences, Immunology, Oncology +12

1–5 of 6